MP24-03 REAL-WORLD UTILIZATION OF APALUTAMIDE AND ENZALUTAMIDE IN NON-METASTATIC CASTRATE RESISTANT PROSTATE CANCER: A RETROSPECTIVE STUDY

You have accessJournal of UrologyProstate Cancer: Advanced (including Drug Therapy) II (MP24)1 Sep 2021MP24-03 REAL-WORLD UTILIZATION OF APALUTAMIDE AND ENZALUTAMIDE IN NON-METASTATIC CASTRATE RESISTANT PROSTATE CANCER: A RETROSPECTIVE STUDY Sreevalsa Appukkuttan, Keely Madaj, Yuxian Du, John Azzolina, Wanda Wilt, Jacqueline Parkin, Jamie Partridge, Sheldon Kong, and Michael Fabrizio AppukkuttanSreevalsa Appukkuttan More articles by this author , MadajKeely Madaj DuYuxian Du AzzolinaJohn Azzolina WiltWanda Wilt ParkinJacqueline Parkin PartridgeJamie Partridge KongSheldon Kong FabrizioMichael View All Author Informationhttps://doi.org/10.1097/JU.0000000000002015.03AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION OBJECTIVE: Management non-metastatic castrate-resistant prostate cancer (nmCRPC) has shifted since the approval three second generation androgen receptor antagonist (ARA), apalutamide (Apa), enzalutamide (Enza) darolutamide (Daro). However, real-world data on these agents are lacking. This study aims assess utilization two new among nmCRPC patients from a urology electronic medical records (EMR) database. METHODS: Patients diagnosed with who initiated Apa or Enza as an initial ARA 2/1/2018 9/30/2020 were retrospectively identified Precision Point Specialty (PPS) Analytics Portal for Prostate Cancer, database containing EMR over 80 active community practices. Due launch timing, Daro was not yet available thus excluded study. Patient demographics, clinical characteristics, patterns reviewed. Survival analyses used describe time discontinuation. supplemental chart review conducted identify reasons dose-reduction RESULTS: total 2,636 identified, 1,023 (39%) 1,613 (61%) Enza. Mean age at initiation 77.8 years 68% self-reporting race white. Median PSA 3.7 ng/dl 4.1 median duration follow-up 18.7 12.1 months therapy 12.9 9.8 respectively. than 41% discontinued use ARA, another 9.4% switching therapy. patient subset randomly selected (N=977; 455 522 Enza). Adverse events (AE) most common reason reported drug discontinuation (43.4% 58.2% Among 5.6% that had dose reduction, 72.4% 73.1% AE (Table 1). CONCLUSIONS: The burden treatment due adverse within is 32% higher in APA 49% trials. Our results show need additional therapies improved safety profiles warrants future studies all agents. Source Funding: Bayer Pharmaceuticals © 2021 American Urological Association Education Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e412-e412 Advertisement Copyright & Permissions© Inc.MetricsAuthor Information Expand Loading ...